These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 25564105)

  • 41. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buprenorphine Enhanced Taper Tolerability Evaluation Report (BETTER): A Case Series.
    Epland C; Pals H; Hayden J
    Subst Use Addctn J; 2024 Oct; 45(4):765-770. PubMed ID: 38591225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment.
    Edelman EJ; Moore BA; Caffrey S; Sikkema KJ; Jones ES; Schottenfeld RS; Fiellin DA; Fiellin LE
    J Addict Med; 2013; 7(6):410-6. PubMed ID: 24189173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characteristics and experiences of buprenorphine-naloxone use among polysubstance users.
    Walker R; Logan TK; Chipley QT; Miller J
    Am J Drug Alcohol Abuse; 2018; 44(6):595-603. PubMed ID: 29693427
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount.
    Jones JD; Manubay JM; Mogali S; Metz VE; Madera G; Martinez S; Mumtaz M; Comer SD
    Drug Alcohol Depend; 2017 Oct; 179():362-369. PubMed ID: 28844013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial.
    Saxon AJ; Ling W; Hillhouse M; Thomas C; Hasson A; Ang A; Doraimani G; Tasissa G; Lokhnygina Y; Leimberger J; Bruce RD; McCarthy J; Wiest K; McLaughlin P; Bilangi R; Cohen A; Woody G; Jacobs P
    Drug Alcohol Depend; 2013 Feb; 128(1-2):71-6. PubMed ID: 22921476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Buprenorphine Induction in Persons With Opioid Use Disorder Hospitalized with Acute Hepatitis A.
    Oller DA; Thornton C; Nuzzo PA; Fanucchi LC
    J Addict Med; 2021 May-Jun 01; 15(3):187-190. PubMed ID: 32909986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation.
    Randall A; Hull I; Martin SA
    J Addict Med; 2023 Mar-Apr 01; 17(2):237-240. PubMed ID: 36149001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.
    Polsky D; Glick HA; Yang J; Subramaniam GA; Poole SA; Woody GE
    Addiction; 2010 Sep; 105(9):1616-24. PubMed ID: 20626379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Causes and risk factors of death among people who inject drugs in Indonesia, Ukraine and Vietnam: findings from HPTN 074 randomized trial.
    Dumchev K; Guo X; Ha TV; Djoerban Z; Zeziulin O; Go VF; Sarasvita R; Metzger DS; Latkin CA; Rose SM; Piwowar-Manning E; Richardson P; Hanscom B; Lancaster KE; Miller WC; Hoffman IF
    BMC Infect Dis; 2023 May; 23(1):319. PubMed ID: 37170118
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regional differences between people who inject drugs in an HIV prevention trial integrating treatment and prevention (HPTN 074): a baseline analysis.
    Lancaster KE; Hoffman IF; Hanscom B; Ha TV; Dumchev K; Susami H; Rose S; Go VF; Reifeis SA; Mollan KR; Hudgens MG; Piwowar-Manning EM; Richardson P; Dvoriak S; Djoerban Z; Kiriazova T; Zeziulin O; Djauzi S; Ahn CV; Latkin C; Metzger D; Burns DN; Sugarman J; Strathdee SA; Eshleman SH; Clarke W; Donnell D; Emel L; Sunner LE; McKinstry L; Sista N; Hamilton EL; Lucas JP; Duong BD; Van Vuong N; Sarasvita R; Miller WC;
    J Int AIDS Soc; 2018 Oct; 21(10):e25195. PubMed ID: 30350406
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short term health-related quality of life improvement during opioid agonist treatment.
    Nosyk B; Bray JW; Wittenberg E; Aden B; Eggman AA; Weiss RD; Potter J; Ang A; Hser YI; Ling W; Schackman BR
    Drug Alcohol Depend; 2015 Dec; 157():121-8. PubMed ID: 26511766
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Positive Social Impacts Related to Participation in an HIV Prevention Trial Involving People Who Inject Drugs.
    Sugarman J; Stalter R; Bokoch K; Liu TY; Donnell D
    IRB; 2015; 37(1):17-9. PubMed ID: 26247080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA.
    Hill LG; Loera LJ; Evoy KE; Renfro ML; Torrez SB; Zagorski CM; Perez JC; Jones SM; Reveles KR
    Addiction; 2021 Jun; 116(6):1505-1511. PubMed ID: 33140519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perioperative Buprenorphine Continuous Maintenance and Administration Simultaneous With Full Opioid Agonist: Patient Priority at the Interface Between Medical Disciplines.
    Acampora GA; Nisavic M; Zhang Y
    J Clin Psychiatry; 2020 Jan; 81(1):. PubMed ID: 31917908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
    Lugoboni F; Zamboni L; Cibin M; Tamburin S;
    Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.